← Back to Screener
TELA Bio, Inc. Common Stock (TELA)
Price$0.63
Favorite Metrics
Price vs S&P 500 (26W)-61.98%
Price vs S&P 500 (4W)-21.74%
Market Capitalization$30.55M
All Metrics
Book Value / Share (Quarterly)$0.14
P/TBV (Annual)10.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)24.68%
Cash Flow / Share (Quarterly)$-0.64
Price vs S&P 500 (YTD)-46.27%
Gross Margin (TTM)67.69%
Net Profit Margin (TTM)-48.37%
EPS (TTM)$-0.83
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-0.83
Revenue Growth (5Y)34.54%
EPS (Annual)$-0.83
ROI (Annual)-62.67%
Gross Margin (Annual)67.69%
Net Profit Margin (5Y Avg)-80.54%
Cash / Share (Quarterly)$1.14
Revenue Growth QoQ (YoY)18.24%
ROA (Last FY)-47.69%
Revenue Growth TTM (YoY)15.84%
EBITD / Share (TTM)$-0.70
ROE (5Y Avg)-294.07%
Operating Margin (TTM)-43.16%
Cash Flow / Share (Annual)$-0.64
P/B Ratio4.84x
P/B Ratio (Quarterly)8.32x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.44x
Net Interest Coverage (TTM)-6.36x
ROA (TTM)-53.97%
EPS Incl Extra (Annual)$-0.83
Current Ratio (Annual)4.20x
Quick Ratio (Quarterly)3.40x
3-Month Avg Trading Volume0.17M
52-Week Price Return-28.66%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.11
P/S Ratio (Annual)0.38x
Asset Turnover (Annual)0.99x
52-Week High$2.20
Operating Margin (5Y Avg)-72.98%
EPS Excl Extra (Annual)$-0.83
CapEx CAGR (5Y)21.39%
Tangible BV CAGR (5Y)-36.08%
26-Week Price Return-53.23%
Quick Ratio (Annual)3.40x
13-Week Price Return-32.40%
Total Debt / Equity (Annual)8.82x
Current Ratio (Quarterly)4.20x
Enterprise Value$35.357
Revenue / Share Growth (5Y)3.96%
Asset Turnover (TTM)1.12x
Book Value / Share Growth (5Y)-47.02%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.18x
Pretax Margin (Annual)-48.09%
Cash / Share (Annual)$1.14
3-Month Return Std Dev95.39%
Gross Margin (5Y Avg)66.50%
Net Income / Employee (TTM)$-0
ROE (Last FY)-615.10%
Net Interest Coverage (Annual)-6.36x
EPS Basic Excl Extra (Annual)$-0.83
Receivables Turnover (TTM)7.85x
Total Debt / Equity (Quarterly)8.82x
EPS Incl Extra (TTM)$-0.83
Receivables Turnover (Annual)7.85x
ROI (TTM)-72.25%
P/S Ratio (TTM)0.38x
Pretax Margin (5Y Avg)-80.53%
Revenue / Share (Annual)$1.71
Tangible BV / Share (Annual)$0.11
Price vs S&P 500 (52W)-63.75%
Year-to-Date Return-42.14%
5-Day Price Return21.86%
EPS Normalized (Annual)$-0.83
ROA (5Y Avg)-53.94%
Net Profit Margin (Annual)-48.37%
Month-to-Date Return10.13%
Cash Flow / Share (TTM)$-1.99
EBITD / Share (Annual)$-0.70
Operating Margin (Annual)-43.16%
LT Debt / Equity (Annual)8.82x
ROI (5Y Avg)-68.36%
LT Debt / Equity (Quarterly)8.82x
EPS Basic Excl Extra (TTM)$-0.83
P/TBV (Quarterly)10.61x
P/B Ratio (Annual)8.32x
Inventory Turnover (TTM)2.18x
Pretax Margin (TTM)-48.09%
Book Value / Share (Annual)$0.14
Price vs S&P 500 (13W)-35.26%
Beta1.06x
Revenue / Share (TTM)$1.55
ROE (TTM)-441.55%
52-Week Low$0.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.09
4.09
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
TELATELA Bio, Inc. Common Stock | 0.38x | 34.54% | 67.69% | -43.16% | $0.63 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
TELA Bio is a medical technology company focused on soft-tissue reconstruction for hernia repair and abdominal wall reconstruction. Its OviTex product portfolio is designed to leverage the body's natural healing response while reducing reliance on permanent synthetic materials. This approach aims to optimize clinical outcomes while preserving patient anatomy.